PMID- 26813918
OWN - NLM
STAT- MEDLINE
DCOM- 20161025
LR  - 20231213
IS  - 1365-3024 (Electronic)
IS  - 0141-9838 (Linking)
VI  - 38
IP  - 4
DP  - 2016 Apr
TI  - Tumour Necrosis Factor-alpha (TNF-alpha) and its soluble receptor type 1 (sTNFR I) in 
      human active and healed leishmaniases.
PG  - 255-60
LID - 10.1111/pim.12305 [doi]
AB  - The role of tumour necrosis factor-alpha (TNF-alpha) is not fully understood in human 
      leishmaniasis. We analysed the alterations in the levels of TNF-alpha, soluble TNF 
      receptor type 1 (sTNFR I), IL-17 and IL-22 productions in active and healed 
      leishmaniases. Blood samples were collected from volunteers with active cutaneous 
      leishmaniasis (ACL), the same subjects after lesion healing (healed CL = HCL), 
      volunteers with active visceral leishmaniasis (AVL), healed VL (HVL) and healthy 
      controls. Levels of cytokines were titrated on Leishmania Ag-stimulated PBMC 
      culture. The mean level of TNF-alpha production from stimulated cells was 
      significantly higher in ACL than controls (P < 0.001) and significantly reduced 
      after treatment in HCL volunteers (P < 0.05). The mean level of sTNFR I 
      production was significantly higher in ACL than controls (P < 0.001) and 
      significantly reduced after treatment in HCL volunteers (P < 0.05). The mean 
      level of IL-22 production in AVL was significantly higher than controls 
      (P < 0.05) and was significantly lower in HVL compared with AVL (P < 0.001) and 
      controls (P < 0.05). The levels of TNF-alpha (P = 0.0025) and sTNFR I (P < 0.01) 
      productions from PBMCs showed significant decreasing trend after treatment in 
      each CL volunteer. Reduction in TNF-alpha is associated with clinical response to 
      treatment and healing of CL lesions due to L. major.
CI  - (c) 2016 John Wiley & Sons Ltd.
FAU - Nateghi Rostami, M
AU  - Nateghi Rostami M
AD  - Department of Microbiology and Immunology, Faculty of Medicine, Qom University of 
      Medical Sciences, Qom, Iran.
AD  - Center for Research and Training in Skin Diseases and Leprosy, Tehran University 
      of Medical Sciences, Tehran, Iran.
FAU - Seyyedan Jasbi, E
AU  - Seyyedan Jasbi E
AD  - Department of Microbiology, Qom Branch, Islamic Azad University, Qom, Iran.
FAU - Khamesipour, A
AU  - Khamesipour A
AD  - Center for Research and Training in Skin Diseases and Leprosy, Tehran University 
      of Medical Sciences, Tehran, Iran.
FAU - Mohammadi, A M
AU  - Mohammadi AM
AD  - Center for Research and Training in Skin Diseases and Leprosy, Tehran University 
      of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Parasite Immunol
JT  - Parasite immunology
JID - 7910948
RN  - 0 (Antiprotozoal Agents)
RN  - 0 (Interleukin-17)
RN  - 0 (Interleukins)
RN  - 0 (Organometallic Compounds)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
RN  - 0 (TNF protein, human)
RN  - 0 (TNFRSF1A protein, human)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 6HG8UB2MUY (Meglumine)
RN  - 75G4TW236W (Meglumine Antimoniate)
SB  - IM
MH  - Adult
MH  - Antiprotozoal Agents/therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Interleukin-17/blood
MH  - Interleukins/blood
MH  - Leishmaniasis, Cutaneous/*blood/drug therapy
MH  - Leishmaniasis, Visceral/*blood/drug therapy
MH  - Male
MH  - Meglumine/therapeutic use
MH  - Meglumine Antimoniate
MH  - Middle Aged
MH  - Organometallic Compounds/therapeutic use
MH  - Receptors, Tumor Necrosis Factor, Type I/*blood
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*blood
MH  - Young Adult
MH  - Interleukin-22
OTO - NOTNLM
OT  - IL-17
OT  - IL22
OT  - TNF-alpha
OT  - cutaneous leishmaniasis
OT  - sTNFR I
EDAT- 2016/01/28 06:00
MHDA- 2016/10/26 06:00
CRDT- 2016/01/28 06:00
PHST- 2015/11/10 00:00 [received]
PHST- 2016/01/15 00:00 [accepted]
PHST- 2016/01/28 06:00 [entrez]
PHST- 2016/01/28 06:00 [pubmed]
PHST- 2016/10/26 06:00 [medline]
AID - 10.1111/pim.12305 [doi]
PST - ppublish
SO  - Parasite Immunol. 2016 Apr;38(4):255-60. doi: 10.1111/pim.12305.